
Follicular Lymphoma


Newly Diagnosed and at Disease Progression (somatic)





Mantle Cell Lymphoma

Newly Diagnosed and at Disease Progression (somatic)





Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

During Treatment/Observation and Relapse (somatic)

When and what should be tested?

- Treatment eligible
- During treatment/observation (MRD) and upon relapse when treatment is indicated
- · Peripheral blood sample
- Bone marrow or lymph node biopsy in select cases

FDA/NCCN approved

- Consider MRD
- · IGHV mutation status
- Del (17p)
- TP53
- Trisomy 12
- del (11q)
- del (13q)
- · CpG-stimulated karyotype
- BTK
- BCL2
- PLCG2


Emerging

- NGS panel
- CARD11



Diffuse Large B-Cell Lymphoma (DLBCL)


Relapsed Disease (somatic)





Lymphoplasmacytic Lymphoma (LPL), Marginal Zone Lymphoma, Hodgkin Lymphoma

Disease Progression (somatic)




- Marginal Zone Lymphoma
 - BTK resistance mutation testing for patients on previous BTK inhibitors
- LPL
 - CXCR4



Multiple Myeloma

During Treatment/Observation and Relapse (somatic)





B-Cell Acute Lymphoblastic Leukemia (ALL) - Adult

At Diagnosis and upon Relapse (somatic)

When and what should be tested?

- Treatment eligible
- During treatment/observation (MRD)
- At diagnosis, upon relapse
- · Peripheral blood sample
- Bone marrow biopsy

FDA/NCCN approved

- BCR-ABL1
- MRD
- Comprehensive NGS
- Chromosomal microarray (CMA)/comparative genomic hybridization (cGH) in cases of aneuploidy or inadequate karyotype
- KMT2A

Informatics

• MLL



Acute Myelogenous Leukemia (AML)

At Diagnosis and upon Relapse (somatic)

When and what should be tested?

- Treatment eligible
- · At time of initial diagnosis and upon relapse
- · Peripheral blood sample
- Bone marrow biopsy

FDA/NCCN approved

- AML
- IDH1
- IDH2
- FLT3
- RUNX1
- NPM1
- CEBPA (in-frame bZIP mutation)
- ASXL1
- C-KIT
- TP53
- MRD
- NGS
- MDS
- MLL (HRX/ALL-1/KMT2A)
- BCOR
- EZH2
- SF3B1
- SRSF2
- STAG2
- U2AF1
- ZRSR2


Emerging

OSMR



Myelodysplastic Syndrome (MDS)

At Diagnosis and upon Relapse (somatic)





Hairy Cell Leukemia

At Diagnosis and upon Relapse (somatic)

When and what should be tested? Treatment eligible All patients in the diagnostic/work-up phase of leukemia classification During treatment/observation (MRD) At time of initial diagnosis or upon relapse Bone marrow biopsy FDA/NCCN approved BRAF MRD IGHV4-34 rearrangement Emerging



· Peripheral blood sample